A virus (strain W161) representing a presumptive new human serotype was isolated from an 18-month-old child with gastroenteritis admitted to Children's Hospital of Philadelphia in February 1983. The W161 virus was clearly distinguished by cross-neutralization tests from human rotaviruses of serotypes 1, 2, 3, and 4, human 69M, and representative bovine (NCDV), porcine (OSU), and chicken (Ch2) rotaviruses. Antisera generated in guinea pigs hyperimmunized to W161 virus displayed a partial cross-reactivity with rotaviruses of human serotypes 1, 2, 3, and 4. Rotaviruses infect virtually all human infants within the first 4 years of life, causing extensive morbidity in all populations and representing one of the leading causes of infant death in the developing world (10). Therefore, there is considerable interest in developing a vaccine against rotavirus (13), and it has been predicted that a reasonably efficacious vaccine would be highly cost-effective (8).
Rotaviruses infect virtually all human infants within the first 4 years of life, causing extensive morbidity in all populations and representing one of the leading causes of infant death in the developing world (10) . Therefore, there is considerable interest in developing a vaccine against rotavirus (13) , and it has been predicted that a reasonably efficacious vaccine would be highly cost-effective (8) .
Although all group A rotaviruses share cross-reactive antigens primarily localized to inner capsid structural polypeptides (12) , specific serotypes may be defined by cross-neutralization tests (18) . Two distinct outer capsid polypeptides, vp3 and vp7, are each capable of eliciting serotype-specific virus-neutralizing antibodies (17, 22) . Several experimental studies in animals have provided evidence suggesting that serotype specificity plays a major role in governing the efficacy of immunoprotection against rotavirus gastroenteritis (3, 14, 23, 28) . Therefore, a complete assessment of extant human rotavirus serotypes is relevant to the design of rotavirus vaccines.
Beards et al. (1) first described distinct human serotypes; human rotavirus isolates were subsequently designated types through 4 as a result of cross plaque-neutralization tests reported by Wyatt et al. (32) . A fifth human serotype designated 69M was recently isolated in Indonesia and described by Matsuno et al. (21) . We relate here a presump-tive additional human serotype described on the basis of isolate W161 recovered from an infant at Children's Hospital, Philadelphia, Pa. Preliminary cross-neutralization studies with reference polyclonal antisera suggest that W161 rotavirus exhibits a minor cross-reaction with rotaviruses of serotypes 1, 2, 3, and 4, which is expressed only on the vp3 surface polypeptide.
MATERIALS AND METHODS
Rotavirus diagnosis. The polyacrylamide gel technique for detection of rotavirus double-stranded RNA has been described elsewhere (9) . In brief, 20 ,ul of a 5% stool suspension was electrophoresed on a 0.8-mm gel consisting of 12% polyacrylamide gel with a 5% stacking gel. The gel was run in a discontinuous (Laemmli) system for 18 h at room temperature at 10 mA of constant current, removed, and stained with silver by a modification of the method of Herring et al. (16) . Enzyme-linked immunosorbent assay (ELISA) for rotavirus in stool was performed by a commercial test (Rotazyme, Abbott Laboratories). Methods employed for electron microscopic analysis of stool and for assay of acute and convalescent serum antibody to rotavirus assessed by ELISA, hemagglutination inhibition, and serum neutralization tests have been described elsewhere (5, 26) .
Virus isolation. MA104 cell culture was purchased from M. A. Bioproducts and cultivated in BHK medium (20 (27) and incubated in a rollertube apparatus at 37°C. Serial passages were performed with suspensions of frozen and thawed whole cultures which were harvested when the entire cell sheet was involved with rotavirus cytopathic effect.
Immune sera. Hyperimmune reference sera were prepared by serial parenteral immunization of guinea pigs as previously described (18) . Preparation of immune sera in mice has been previously described (23) . In brief, 8-week-old female CD-1 mice were either inoculated orally three times at 2-week intervals with 6 x 106 PFU of virus (oral mice) or inoculated initially with the same dose of virus emulsified in complete Freund adjuvant and inoculated intraperitoneally, followed by a second intraperitoneal dose of the same virus titer emulsified in incomplete Freund adjuvant and administered 6 weeks later (intraperitoneal mice). Immune serum was collected 21 days after the final rotavirus inoculation.
Virus. The method of propagation (26) Inoculation of newborn mice and calves. Newborn mice were inoculated as described previously (25 
RESULTS
Isolation. An 18-month-old girl with a history of chronic failure to thrive was admitted to Children's Hospital on 11 February 1983. Her medical history was notable for omphalocele and congenital heart disease. Despite surgical correction of both clinical conditions, the child continued to have difficulties gaining weight. Upon presentation to the Emergency Department at Children's Hospital, the child was noted to have vomiting and fever and was admitted for dehydration and suspected small bowel obstruction. Epidemiologically, the child had no exposure to animals and did not have an unusual travel history or diet. The child did not attend day care, and no other family members were ill at the time.
Rotavirus was detected in a stool sample collected 3 days postadmission by electron microscopic and polyacrylamide gel analysis for rotaviral RNA (9) but not by ELISA (Rotazyme, Abbott Laboratories). Serum antibody analysis suggested strongly that the infant was seropositive for rotavirus antibody before this infection, as indicated by high concentrations of rotavirus-specific antibody detected by serum ELISA, radioimmune precipitation tests, and neutralization antibody titers to serotypes 1 and 3 and homotypic virus, all determined in a serum sample collected 1 day after the onset of disease. A marked increase in antibody titer was detected in a serum sample collected 21 days after onset of disease; convalescent ELISA and hemagglutination inhibition titers and titers of neutralizing antibodies to serotype 1 and homotypic (WI61) rotavirus were the highest that we have observed in a natural infection (5) .
Virus isolation studies were performed with a suspension of stool collected on day 3 after onset of disease. The stool suspension was treated with trypsin, and roller-tube cultures of MA104 cells were infected by the methods reported by Sato et al. (27) and Urasawa et al. (30) . Cytopathic effect was observed within 5 days after inoculation. Serial passage into stationary MA104 cell culture was readily accomplished after the first passage. Clear plaques were induced in MA104 cells. By passage 5, yields of approximately 1070 PFU/ml were obtained 3 to 5 days after cell culture inoculation at a multiplicity of infection of 1.0. The virus was given the strain designation WI61 based upon the identification number of the patient.
Subgroup. The subgroup of W161 rotavirus was determined to be Il by an ELISA system employing monoclonal antibodies (15 (12) .
Cross-neutralization reactions of WI61 virus with human rotaviruses of serotypes 1 to 4 and bovine rotavirus strain NCDV were also compared with immune sera prepared in adult mice inoculated parenterally or orally (23) . Sera of parenterally inoculated mice indicated that WI61 virus is a completely distinct serotype. Although minor reciprocal cross-reactions were detected between W161 virus and each of the other serotypes, particularly when antisera to WI61 virus were reacted with heterotypic viruses, none approached the >5% of homologous titer level used to delineate rotavirus serotypes (18) .
More extensive cross-reactions were observed with the lower titered antisera induced in orally immunized mice ( Table 2) . As previously observed with guinea pig-derived antisera, cross-reactions were predominantly one-way, i.e., only detectable when antisera to WI61 virus were reacted with heterotypic viruses.
Evidence of cross-reactivity with heterotypic virus was also detected in human infants. In a series of 11 seronegative infants (aged 5 to 11 months) inoculated orally with WC3 bovine-derived rotavirus vaccine (6) interest to determine the naturally occurring incidence of antibody to W161. The observed incidences of antibody to W161 in adult and infant sera are shown in Table 3 . Antibody to WI61 was detected in 17 of 18 normal adult sera (healthy adult volunteers, residents of Philadelphia, Pa., aged 18 to 63 years). The median antibody titer to WI61 was similar to that against SA11 (serotype 3) and greater than that to Wa rotavirus (serotype 1). In 10 of 18 adults, the titer to W161 was higher than that against either Wa or SA11 rotavirus. The high incidence and titer of antibody to W161 in adults is reflected in the observation that six of seven infants aged 2 to 4 months exhibited antibody to W161; at this age, serum-neutralizing antibody against rotavirus is presumed to most often represent maternally acquired antibody (29) . Antibody to rotavirus was infrequently observed at age 5 to 11 months. In sera of infants aged 12 to 26 months collected both in Philadelphia and in Japan, a high incidence of antibody was observed to WI61, as well as to Wa and SA11, strain rotaviruses.
It was also of interest to determine whether any evidence of exposure to WI61 rotaviruses is present in domestic animals. Inasmuch as we had previously determined that sera and milk of individual cows, as well as commercial milk samples obtained over the counter, often contain neutralizing antibody to rotavirus of human serotypes (Groff and Clark, unpublished data; also reported by Yolken et al. [33] , Snodgrass et al. [28] , and Ebina et al. [11] ), we assayed the neutralizing antibody to WI61 in seven commercial milk samples (Table 4 ). Each contained antibody that neutralized (2) .
Titration of W161 virus in orally inoculated mice revealed a 50% incidence of gastroenteritis at a dose of 107.0 PFU, the highest titer obtainable without concentration of virus. No disease was induced with W161 doses of less than 107.0 PFU.
(ii) Newborn calf. Because of the high incidence of W161 virus-specific antibody in bovine milk, it was of special interest to determine the infectivity of WI61 virus in the newborn calf model system. A single gnotobiotic calf (Holstein-Fresian), 24 The WI61 rotavirus differs from the previously described human group A rotaviruses in that it frequently elicits cross-reactive PRN antibody to rotaviruses of serotypes 1 to 4. This is a one-way cross-reaction unaccompanied by cross-neutralization of W161 virus by antiseta to heterotypic rotaviruses. The cross-reactivity has been tentatively localized to the gene 4 (vp3) product of WI61 virus; the gene 9 (vp7) product is therefore apparently unique. The latter observation has been confirmed by the detection of numerous differences in the nucleotide sequence of gene 9 of WI61 compared with the vp7-coding genes of heterotypic human rotavirus strains (K. Green and J. Flores, personal communication). The recent observation that the two rotavirus structural polypeptides vp3 and vp7 play an important role both in eliciting PRN antibodies to rotavirus (17, 22) and in immunoprotection (24) suggests that a ne'w strategy for rotavirus nomenclature that takes each of these independent antigens into account may be required. 
